Cargando…

Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging

PURPOSE: To use (18) F-FDG microPET dynamic imaging to preliminarily identify the changes of myocardial glucose metabolism corresponding to different functional phenotypes of diabetic cardiomyopathy (DCM) in mice and elucidate their relationships. METHODS: Left ventricular function was measured by e...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Xiaoliang, Liu, Yaqi, Zhou, Mingge, Xu, Min, Chen, Yuqi, Huang, Hongbo, Lin, Jianguo, Wang, Yuetao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067248/
https://www.ncbi.nlm.nih.gov/pubmed/37005683
http://dx.doi.org/10.1186/s13098-023-01038-5
_version_ 1785018425773391872
author Shao, Xiaoliang
Liu, Yaqi
Zhou, Mingge
Xu, Min
Chen, Yuqi
Huang, Hongbo
Lin, Jianguo
Wang, Yuetao
author_facet Shao, Xiaoliang
Liu, Yaqi
Zhou, Mingge
Xu, Min
Chen, Yuqi
Huang, Hongbo
Lin, Jianguo
Wang, Yuetao
author_sort Shao, Xiaoliang
collection PubMed
description PURPOSE: To use (18) F-FDG microPET dynamic imaging to preliminarily identify the changes of myocardial glucose metabolism corresponding to different functional phenotypes of diabetic cardiomyopathy (DCM) in mice and elucidate their relationships. METHODS: Left ventricular function was measured by echocardiography in C57BL/KsJ-db/db (db/db) mice and their controls at 8, 12, 16, and 20 weeks of age to divide DCM stages and functional phenotypes. Myocardial histopathology was used to verify the staging accuracy and list-mode microPET dynamic imaging was conducted. The myocardial metabolic rate of glucose (MRglu) and the glucose uptake rate constant (Ki) were derived via Patlak graphical analysis, and the differences in myocardial glucose metabolism levels in different DCM stages were compared. The key proteins involved in myocardial glucose metabolism signaling pathway were analyzed by Western blotting to elucidate the underlying mechanism of abnormal glucose metabolism in DCM. RESULTS: Compared with the controls, the ratio of early diastolic transmitral flow velocity to early diastolic mitral annular tissue velocity (E/e’) of db/db mice was significantly increased from the age of 12 weeks, while the left ventricular ejection fraction (LVEF) was significantly decreased from the age of 16 weeks (all P < 0.05). Based on the staging criteria, 8 and 12 weeks (8/12w) db/db mice were in DCM stage 1 (diastolic dysfunction with normal LVEF), and 16 and 20 weeks (16/20w) db/db mice were in DCM stage 2/3 (diastolic and systolic dysfunction). The degree of myocardial fibrosis, glycogen deposition and ultrastructural damage in 16/20w db/db mice were more obvious than those in 8/12w group. The myocardial MRglu, Ki of db/db mice in 8/12w group or 16/20w group were significantly lower than those in the control group (all P < 0.05), while the myocardial standard uptake value (SUV) was not significantly reduced in the 8/12w group compared with the control group (P > 0.05). MRglu and SUV were moderately negatively correlated with the E/e’ ratio (r=-0.539 and − 0.512, P = 0.007 and 0.011), which were not significantly correlated with LVEF (P > 0.05). Meanwhile, Ki was not significantly correlated with LVEF or E/e’ ratio. The decreased expression of glucose transporter (GLUT) -4 in db/db mice preceded GLUT-1 and was accompanied by decreased phosphorylated AMP-activated protein kinase (p-AMPK) expression. Myocardial MRglu, Ki and SUV were significantly positively correlated with the expression of GLUT-4 (MRglu: r = 0.537; Ki: r = 0.818; SUV: r = 0.491; P = 0.000 ~ 0.046), but there was no significant correlation with GLUT-1 expression (P = 0.238 ~ 0.780). CONCLUSIONS: During the progression of DCM, with the changes of left ventricular functional phenotype, abnormal and dynamic changes of myocardial glucose metabolism can occur in the early stage. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-023-01038-5.
format Online
Article
Text
id pubmed-10067248
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100672482023-04-03 Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging Shao, Xiaoliang Liu, Yaqi Zhou, Mingge Xu, Min Chen, Yuqi Huang, Hongbo Lin, Jianguo Wang, Yuetao Diabetol Metab Syndr Research PURPOSE: To use (18) F-FDG microPET dynamic imaging to preliminarily identify the changes of myocardial glucose metabolism corresponding to different functional phenotypes of diabetic cardiomyopathy (DCM) in mice and elucidate their relationships. METHODS: Left ventricular function was measured by echocardiography in C57BL/KsJ-db/db (db/db) mice and their controls at 8, 12, 16, and 20 weeks of age to divide DCM stages and functional phenotypes. Myocardial histopathology was used to verify the staging accuracy and list-mode microPET dynamic imaging was conducted. The myocardial metabolic rate of glucose (MRglu) and the glucose uptake rate constant (Ki) were derived via Patlak graphical analysis, and the differences in myocardial glucose metabolism levels in different DCM stages were compared. The key proteins involved in myocardial glucose metabolism signaling pathway were analyzed by Western blotting to elucidate the underlying mechanism of abnormal glucose metabolism in DCM. RESULTS: Compared with the controls, the ratio of early diastolic transmitral flow velocity to early diastolic mitral annular tissue velocity (E/e’) of db/db mice was significantly increased from the age of 12 weeks, while the left ventricular ejection fraction (LVEF) was significantly decreased from the age of 16 weeks (all P < 0.05). Based on the staging criteria, 8 and 12 weeks (8/12w) db/db mice were in DCM stage 1 (diastolic dysfunction with normal LVEF), and 16 and 20 weeks (16/20w) db/db mice were in DCM stage 2/3 (diastolic and systolic dysfunction). The degree of myocardial fibrosis, glycogen deposition and ultrastructural damage in 16/20w db/db mice were more obvious than those in 8/12w group. The myocardial MRglu, Ki of db/db mice in 8/12w group or 16/20w group were significantly lower than those in the control group (all P < 0.05), while the myocardial standard uptake value (SUV) was not significantly reduced in the 8/12w group compared with the control group (P > 0.05). MRglu and SUV were moderately negatively correlated with the E/e’ ratio (r=-0.539 and − 0.512, P = 0.007 and 0.011), which were not significantly correlated with LVEF (P > 0.05). Meanwhile, Ki was not significantly correlated with LVEF or E/e’ ratio. The decreased expression of glucose transporter (GLUT) -4 in db/db mice preceded GLUT-1 and was accompanied by decreased phosphorylated AMP-activated protein kinase (p-AMPK) expression. Myocardial MRglu, Ki and SUV were significantly positively correlated with the expression of GLUT-4 (MRglu: r = 0.537; Ki: r = 0.818; SUV: r = 0.491; P = 0.000 ~ 0.046), but there was no significant correlation with GLUT-1 expression (P = 0.238 ~ 0.780). CONCLUSIONS: During the progression of DCM, with the changes of left ventricular functional phenotype, abnormal and dynamic changes of myocardial glucose metabolism can occur in the early stage. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-023-01038-5. BioMed Central 2023-04-01 /pmc/articles/PMC10067248/ /pubmed/37005683 http://dx.doi.org/10.1186/s13098-023-01038-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shao, Xiaoliang
Liu, Yaqi
Zhou, Mingge
Xu, Min
Chen, Yuqi
Huang, Hongbo
Lin, Jianguo
Wang, Yuetao
Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging
title Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging
title_full Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging
title_fullStr Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging
title_full_unstemmed Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging
title_short Dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) F-FDG microPET myocardial metabolic imaging
title_sort dynamic evolution and mechanism of myocardial glucose metabolism in different functional phenotypes of diabetic cardiomyopathy — a study based on (18) f-fdg micropet myocardial metabolic imaging
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067248/
https://www.ncbi.nlm.nih.gov/pubmed/37005683
http://dx.doi.org/10.1186/s13098-023-01038-5
work_keys_str_mv AT shaoxiaoliang dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT liuyaqi dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT zhoumingge dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT xumin dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT chenyuqi dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT huanghongbo dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT linjianguo dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging
AT wangyuetao dynamicevolutionandmechanismofmyocardialglucosemetabolismindifferentfunctionalphenotypesofdiabeticcardiomyopathyastudybasedon18ffdgmicropetmyocardialmetabolicimaging